GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » JW (Cayman) Therapeutics Co Ltd (OTCPK:JWCTF) » Definitions » Research & Development

JW (Cayman) Therapeutics Co (JW (Cayman) Therapeutics Co) Research & Development : $60.64 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is JW (Cayman) Therapeutics Co Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. JW (Cayman) Therapeutics Co's Research & Development for the six months ended in Dec. 2023 was $0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 was $60.64 Mil.


JW (Cayman) Therapeutics Co Research & Development Historical Data

The historical data trend for JW (Cayman) Therapeutics Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

JW (Cayman) Therapeutics Co Research & Development Chart

JW (Cayman) Therapeutics Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial 19.41 34.44 65.06 58.50 57.93

JW (Cayman) Therapeutics Co Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 35.94 29.26 30.40 30.24 -

JW (Cayman) Therapeutics Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $60.64 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


JW (Cayman) Therapeutics Co  (OTCPK:JWCTF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


JW (Cayman) Therapeutics Co Research & Development Related Terms

Thank you for viewing the detailed overview of JW (Cayman) Therapeutics Co's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


JW (Cayman) Therapeutics Co (JW (Cayman) Therapeutics Co) Business Description

Traded in Other Exchanges
Address
No. 699 Zhong Ke Road, 5F, Building B, Pudong New District, Shanghai, CHN
JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.

JW (Cayman) Therapeutics Co (JW (Cayman) Therapeutics Co) Headlines

No Headlines